Skip to main content
SpringerLink
Log in

Postmenopausal Breast Cancer

Drug Therapy in the 1990s

  • Review Article
  • Drug Therapy
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

In summarising current drug treatment strategies for postmenopausal women with breast cancer, it is essential to emphasise that we are dealing with a group of diseases that are treatable, and that appropriate treatment decisions will give longer disease-free intervals for patients with early breast cancer, and better control with better survival for patients with advanced (i.e. locally advanced and/or metastatic) disease.

Women greater than 65 years of age have a predictably better response to hormone treatment versus women less than 65 years of age. Hormone treatment may, therefore, be considered as primary treatment or as adjuvant treatment after limited surgery. Hormone treatment is also the treatment of first choice for elderly patients with advanced disease.

For middle-aged women (45 to 65 years of age), various patient factors are important in predicting the value of treatment. Estrogen receptor (ER) status is prognostic of survival irrespective of treatment. Patients with ER-positive disease have a better prognosis than those with ER-negative disease, both in the adjuvant setting and in the face of metastatic disease. This is because ER-positive tumours tend to grow slower. The availability of the serotonin type 3 (5-hydroxytryptamine; 5-HT3) antagonists, which effectively control nausea and vomiting in most patients, make chemotherapy combinations more acceptable, and combination chemotherapy can more readily be considered as first treatment option both as adjuvant treatment and for treatment of advanced disease. For patients with organ metastases there is no doubt that combined chemotherapy treatment is indicated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • A’Hern RP, Ebbs SR, Baum MB. Does chemotherapy improve survival in advanced breast cancer? A statistical overview. British Journal of Cancer 57: 615–618, 1988

    Article  PubMed  Google Scholar 

  • Ahlemann LM, Heil M, Staab HJ. Droloxifene: intermittent therapy in metastatic breast cancer. Abstract C030. Journal of Steroid Biochemistry and Molecular Biology 28: 108S, 1987

    Google Scholar 

  • Ahmann DL, Schaid DJ, Bisel HF, Hahn RG, Edmonson JH, et al. The effect on survival of initial chemotherapy in advanced breast cancer: polychemotherapy versus single drug. Journal of Clinical Oncology 5: 1928–1932, 1987

    PubMed  CAS  Google Scholar 

  • Ahmann DL, Schaid DJ, Ingle JN, Bisel HF, Schutt AJ, et al. A randomized trial of cyclophosphamide, doxorubicin and prednisone versus cyclophosphamide, 5-fluorouracil and prednisone in patients with metastatic breast cancer. American Journal of Clinical Oncology 14: 179–183, 1991

    Article  PubMed  CAS  Google Scholar 

  • Aisner J, Weinberg V, Perloff M, Weiss R, Perry M, et al. Chemotherapy versus chemoimmunotherapy (CAF versus CAFVP versus CMF each ± MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B. Journal of Clinical Oncology 5: 1523–1533, 1987

    PubMed  CAS  Google Scholar 

  • Alanko A, Heinonen E, Scheinin T, Tolppanen EM, Vihko R. Significance of estrogen and progesterone receptors, disease-free interval, and site of first metastases on survival of breast cancer patients. Cancer 56: 1696–1700, 1985

    Article  PubMed  CAS  Google Scholar 

  • Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. Journal of Clinical Oncology 4: 186–193, 1986

    Google Scholar 

  • Baker LH, Vaughn CB, al-Sarraf M, Reed ML, Vaitkeviciuss VH. Proceedings. Evaluation of combination versus sequential cytotoxic chemotherapy in the treatment of advanced breast cancer. Cancer 33: 513–518, 1974

    Article  PubMed  CAS  Google Scholar 

  • Beltrán M, Alonso MC, Ojeda MB, Izquierdo A, Ferrer J, et al. Alternative sequential endocrine therapy: Tamoxifen and medroxyprogesterone acetate versus tamoxifen in postmenopausal advanced breast cancer patients. Annals of Oncology 2: 495–499, 1991

    PubMed  Google Scholar 

  • Bennett JM, Muss HB, Doroshow JH, Wolff S, Krementz ET, et al. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide and fluorouracil with doxorubicin, cyclophosphamide and fluorouracil in the therapy of metastatic breast carcinoma. Journal of Clinical Oncology 6: 1611–1620, 1988

    PubMed  CAS  Google Scholar 

  • Bernardo-Strada MR, Imparato E, Aspesi G, Pavesi L, Robustelli Della Cuna G. Oral high doses of medroxyprogesterone acetate (MPA) in the treatment of advanced breast and endometrial carcinoma. Minerva Medica 71: 3241–3246, 1980

    PubMed  CAS  Google Scholar 

  • Bonadonna G, Veronesi U. Primary medical therapy: Milan experience. In Powles & Smith (Eds) Medical management of breast cancer, pp. 267–271, Martin Dunitz, London, 1991

    Google Scholar 

  • Brinckner H. Distant recurrence in breast cancer. Survival expectations and first choice of chemotherapy regimen. Acta Oncologica 27: 729–732, 1988

    Article  Google Scholar 

  • Brinckner H, Rose C, van der Maase H, Dombernowsky P. A randomized study of CAF + TAM (tamoxifen) vs CMF + TAM in metastatic breast cancer. Proceedings of the American Association of Cancer Research 3: 113, 1984

    Google Scholar 

  • Bull JM, Tormey DC, Shou-Hua Li, Carbone PP, Falkson G, et al. A randomized comparative trial of doxorubicin versus methotrexate in combination drug therapy. Cancer 41: 1649–1657, 1978

    Article  PubMed  CAS  Google Scholar 

  • Canellos GP, Pocock SJ, Taylor SG III, Sears ME, Klaasen DJ, et al. Combination chemotherapy for metastatic breast carcinoma: prospective comparison of multiple-drug therapy with L-phenylalanine mustard. Cancer 38: 1882–1886, 1976

    Article  PubMed  CAS  Google Scholar 

  • Carmo-Pereira J, Costa FO, Henriques E. Chemotherapy of advanced breast cancer: a randomized trial of vincristine, adriamycin, and cyclophosphamide (VAC) versus cyclophosphamide, methotrexate, 5-fluorouracil and prednisone (CMFP). Cancer 48: 1517–1521, 1981

    Article  PubMed  CAS  Google Scholar 

  • Chang YC, Falkson G, Tormey DC, Crowley J. A pilot study of mitomycin-C and tamoxifen (MT) versus mitolactol, adriamycin and tamoxifen (DAT). American Journal of Clinical Oncology — Cancer Clinical Trials 5: 521–525, 1982

    CAS  Google Scholar 

  • Chlebowski RT, Irwin LE, Pugh RP, Sadoff L, Hestroff R, et al. Survival of patients with metastatic breast cancer treated with either combination or sequential chemotherapy. Cancer Research 39: 4503–4506, 1979

    PubMed  CAS  Google Scholar 

  • Chlebowski RT, Smalley RV, Weiner JM, Irwin LE, Bartolucci AA, et al. Combination versus sequential single agent chemotherapy in advanced breast cancer: associations with metastatic sites and long-term survival. The Western Cancer Study Group and the Southeastern Cancer Study Group. British Journal of Cancer 59: 227–230, 1989

    Article  PubMed  CAS  Google Scholar 

  • Clark GM, Sledge Jr GW, Osborne CK, McGuire WL. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. Journal of Clinical Oncology 5: 55–61, 1987

    PubMed  CAS  Google Scholar 

  • Coates A, Gebski V, Bishop JF, Jeal PN, Australian-New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. New England Journal of Medicine 317: 1490–1495, 1987

    Article  PubMed  CAS  Google Scholar 

  • Cohen M, Rajendra R, Ahuja N, Nguyen D. Chemotherapy dose intensity (CI-DI) and median survival (MS) in advanced breast cancer: no apparent relationship. Abstract 126. Proceedings of the American Society of Clinical Oncology 9: 34, 1990

    Google Scholar 

  • Coleman RE, Woll PJ, Miles M, Scrivener W, Rubens RD. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropilidene)-1, 1-biphosphonate (APD). British Journal of Cancer 58: 621–625, 1988

    Article  PubMed  CAS  Google Scholar 

  • Congdon J, Green S, O’Sullivan J, Hynes H, Belt R, et al. Megesterol acetate (MA) and aminoglutethimide/hydrocortisone (AG) in sequence or in combination as second-line endocrine therapy of estrogen receptor positive metastatic breast cancer. Abstract 45. Proceedings of American Society of Clinical Oncology 10: 43, 1991

    Google Scholar 

  • Coombes RC. 4-Hydroxyandrostenedione (4-OHA) treatment for postmenopausal patients with advanced breast cancer. Abstract 209. 4th International Congress on Hormones and Cancer, 1991

  • Creech RH, Catalano RB, Harris DT, Engstrom PF, Grotzinger PJ. Low-dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin. Cancer 43: 51–59, 1979

    Article  PubMed  CAS  Google Scholar 

  • Cummings FJ, Gelman R, Horton J. Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors. Journal of Clinical Oncology 3: 932–940, 1985b

    PubMed  CAS  Google Scholar 

  • Cummings FJ, Gray R, Davis TE, Tormey DC, Harris JE, et al. Adjuvant tamoxifen treatment of elderly women with stage II breast cancer. A double-blind comparison with placebo. Annals of Internal Medicine 103: 324–329, 1985a

    PubMed  CAS  Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group. The effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,896 women. New England Journal of Medicine 319: 1681–1692, 1988

    Article  Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group. Adjuvant endocrine and cytotoxic therapy in early breast cancer: a systemic overview of all available randomized trials. First report of the Early Breast Cancer Trialists’ Collaborative Group, Oxford University Press, Oxford, 1990

    Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 1–15, 1992

    Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 71–85, 1992

    Google Scholar 

  • Elomaa I, Blomqvist C, Porkka L, Holmström T, Taube T, et al. Diphosphonates for osteolytic metastases. Lancet 1: 1155–1166, 1985

    Article  PubMed  CAS  Google Scholar 

  • Elomaa I, Blomqvist C, Gröhn C, Porkka L, Kairento AL, et al. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet 1: 146–149, 1983

    Article  PubMed  CAS  Google Scholar 

  • Ettinger DS, Allegra J, Bertino JR, Bonomi P, Browder H, et al. Megestrol acetate versus tamoxifen in advanced breast cancer: correlation of hormone receptors and response. Seminars in Oncology 13: 9–14, 1986

    PubMed  CAS  Google Scholar 

  • Falkson CI, Falkson HC, Falkson G. High-dose medroxyprogesterone acetate plus mitomycin-C or vindesine in the treatment of advanced breast cancer. American Journal of Clinical Oncology — Cancer Clinical Trials 11: 431–434, 1988

    Article  CAS  Google Scholar 

  • Falkson G, Falkson HC. A phase II study of high-dose medroxyprogesterone acetate in advanced breast cancer. Cancer Chemotherapy and Pharmacology 11: 16–18, 1983

    PubMed  CAS  Google Scholar 

  • Falkson G, Gelman RS, Dreicer R, Tormey DC, Alberts AS, et al. Myelodysplastic syndrome and acute nonlymphocytic leukemia secondary to mitolactol treatment in patients with breast cancer. Journal of Clinical Oncology 7: 1252–1259, 1989

    PubMed  CAS  Google Scholar 

  • Falkson G, Gelman R, Falkson CI, Glick J, Harris J. Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: A prospective study. Journal of Clinical Oncology 9: 2153–2161, 1991a

    PubMed  CAS  Google Scholar 

  • Falkson G, Gelman RS, Glick JH. The induction efficacy of DAVTH (dibromodulcitol, adriamycin, vincristine, tamoxifen and fluoxymesterone) in the treatment of patients with metastatic breast cancer — an ECOG study. Abstract 188. Proceedings of the American Society of Clinical Oncology 6: 200, 1987b

    Google Scholar 

  • Falkson G, Gelman RS, Pretorius FJ. Age as a prognostic factor in recurrent breast cancer. Journal of Clinical Oncology 4: 663–671, 1986a

    PubMed  CAS  Google Scholar 

  • Falkson G, Gelman RS, Tormey DC, Cummings FJ, Carbone PP, et al. The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. Cancer 56: 219–224, 1985a

    Article  PubMed  CAS  Google Scholar 

  • Falkson G, Gelman RS, Tormey DC, Falkson CI, Wolter JM, et al. Treatment of metastatic breast cancer in premenopausal women using CAF with or without oophorectomy: an Eastern Cooperative Oncology Group Study. Journal of Clinical Oncology 5: 881–889, 1987a

    PubMed  CAS  Google Scholar 

  • Falkson G, Gelman RS, Tormey DC, Taylow SG IV, Falkson HC. Mitomycin-C and tamoxifen versus mitolactol, doxorubicin and tamoxifen in patients with previously treated breast cancer. Cancer Treatment Reports 69: 755–760, 1985b

    PubMed  CAS  Google Scholar 

  • Falkson G, Klein B, Falkson H. Hematological toxicity: experience with anthracyclines and anthracenes. Experimental Hematology 13: 64–71, 1985c

    PubMed  CAS  Google Scholar 

  • Falkson G, Snyman HW. Experience with chemotherapy of cancer at the University of Pretoria. Acto Unio Internationalis Contra Cancrum 20: 439–446, 1964

    CAS  Google Scholar 

  • Falkson G, Tormey DC, Carey P, Whitte R, Falkson HC. Fifteen year survival data on patients treated with combination chemotherapy for metastatic breast cancer. European Journal of Cancer 27: 973–977, 1991b

    Article  PubMed  CAS  Google Scholar 

  • Falkson G, van Dyk JJ, Tormey DC. A 4-drug combination investigated in patients with advanced breast cancer. Indian Journal of Cancer Chemotherapy 3: 3–6, 1981

    Google Scholar 

  • Falkson HC, Falkson G. High-dose medroxyprogesterone acetate in combination with vindesine in advanced breast cancer. European Journal of Cancer 22: 1511–1514, 1986b

    Article  CAS  Google Scholar 

  • Falkson HC, Gray R, Wolberg WH, Gillchrist WK, Harris JE, et al. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus 4 cycles of CMFPT in postmenopausal women with breast cancer — an ECOG phase III study. Journal of Clinical Oncology 8: 599–607, 1990

    PubMed  CAS  Google Scholar 

  • Fisher B, Redmond C, Legault-Poisson S, Dimitrov NV, Brown AM, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. Journal of Clinical Oncology 8: 1005–1018, 1990

    PubMed  CAS  Google Scholar 

  • Fisher B, Wickerham DL. Preoperative systemic therapy for the treatment of primary breast cancer. In Powles & Smith (Eds) Medical management of breast cancer, pp. 281–286, Martin Dunitz, London, 1991

    Google Scholar 

  • Forrest APM, Anderson EDC. Primary medical therapy: Edinburgh experience. In Powles & Smith (Eds) Medical management of breast cancer, pp. 273–280, Martin Dunitz, London, 1991

    Google Scholar 

  • Frei III E, Antman K, Teicher B, Elder P, Schnipper L. Bone marrow autotransplantation for solid tumors — prospects. Journal of Clinical Oncology 7: 515–526, 1989

    PubMed  Google Scholar 

  • Goldhirsch A, Gelber R. Adjuvant treatment for early breast cancer: the Ludwig Breast Cancer Studies. NCI Monograph 55–70, 1986

    Google Scholar 

  • Goldhirsch A, Gelber RD, Simes RJ, Glasziou P, Coates AS. Costs and benefits of adjuvant therapy in breast cancer: a quality adjusted survival analysis. Journal of Clinical Oncology 7: 36–44, 1989

    PubMed  CAS  Google Scholar 

  • Grem JL, Falkson G, Love RR, Tormey DC. A Phase II evaluation of combination chemotherapy plus aminoglutethamide in women with metastatic or recurrent breast cancer. American Journal of Clinical Oncology (Cancer Clinical Trials) 11: 528–534, 1988

    Article  CAS  Google Scholar 

  • Hart RD, Perloff M, Holland JF. One day VATH (vinblastine, adriamycin, thiotepa and halotestin) therapy for advanced breast cancer refractory to chemotherapy. Cancer 48: 1522–1527, 1981

    Article  PubMed  CAS  Google Scholar 

  • Henderson IC, Shapiro CL. Adjuvant chemotherapy — an overview. In Powles & Smith (Eds) Medical management of breast cancer, pp. 197–216, Martin Dunitz, London, 1991

    Google Scholar 

  • Hoogenstraten B, Irwin L, Ahmann D. Breast cancer: proposed guidelines — report from the combination chemotherapy trials working group. In Carbone & Sears (Eds) Breast cancer: suggested protocol guidelines for combination chemotherapy trials and for combined modality trials, pp. 4–19, DHEW Publication No. National Institutes of Health 77-1192, Washington, DC, 1977

    Google Scholar 

  • Hortobagyi GN, Buzdar AU, Frye D, Yap HY, Hug V, et al. Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer. Breast Cancer Research and Treatment 5: 321–326, 1985

    Article  PubMed  CAS  Google Scholar 

  • Høst H, Lund E. Age as a prognostic factor in breast cancer. Cancer 57: 2217–2221, 1986

    Article  PubMed  Google Scholar 

  • Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. Journal of Clinical Oncology 2: 1281–1288, 1984

    PubMed  CAS  Google Scholar 

  • Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Creagan ET, et al. Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. American Journal of Clinical Oncology 5: 155–160, 1982

    Article  PubMed  CAS  Google Scholar 

  • Ingle JN, Mailliard JA, Schaid DJ, Krook JE, Gesme DH, et al. A double-blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. Cancer 68: 34–39, 1991a

    Article  PubMed  CAS  Google Scholar 

  • Ingle JN, Pfeifle DM, Green SJ, Kvols LK, Brunk SF, et al. Randomized clinical trial of doxorubicin alone or combined with mitolactol in women with advanced breast cancer and prior chemotherapy exposure. American Journal of Clinical Oncology — Cancer Clinical Trials 8: 275–282, 1985

    Article  CAS  Google Scholar 

  • Ingle JN, Twito DI, Schaid DJ, Cullinan SA, Krook JE, et al. Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer: an updated analysis. Cancer 67: 886–891, 1991b

    Article  PubMed  CAS  Google Scholar 

  • Jackson IM, Litherland S, Wakeling AE. Tamoxifen and other antioestrogens: Edinburgh experience. In Powles and Smith (Eds) Medical management of breast cancer, pp. 51–59, Martin Dunitz, London, 1991

    Google Scholar 

  • Jamison RN, Burish TG, Wallston KA. Psychogenic factors in predicting survival of breast cancer patients. Journal of Clinical Oncology 5: 768–772, 1987

    PubMed  CAS  Google Scholar 

  • Kardinal CG, Perry MC, Korzun AH, Rice MA, Ginsberg S, et al. Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy. A subset analysis of CALGB study 8081. Cancer 61: 415–419, 1988

    Article  PubMed  CAS  Google Scholar 

  • Leonard RC, Cornbleet MA, Kaye SB, Soukop M, White G, et al. Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast. Journal of Clinical Oncology 5: 1056–1063, 1987

    PubMed  CAS  Google Scholar 

  • Lipton A, Harvey HA, Santen RT, Boucher A, White D, et al. A randomized trial of aminoglutethamide versus tamoxifen in metastatic breast cancer. Cancer Research 42: 3434s–3436s, 1982

    PubMed  CAS  Google Scholar 

  • Loprinzi CL, Tormey DC, Rasmussen P, Falkson G, Davis TE, et al. Prospective evaluation of carcinoembryonic antigen levels and alternative chemotherapeutic regimens in metastatic breast cancer. Journal of Clinical Oncology 4: 46–56, 1986

    PubMed  CAS  Google Scholar 

  • Mansour EG, Gray R, Shatila AH, Osborne CK, Tormey DC, et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. New England Journal of Medicine 320: 485–490, 1989

    Article  PubMed  CAS  Google Scholar 

  • Mattson W. A phase III trial of treatment with tamoxifen versus high-dose medroxyprogesterone acetate in advanced postmenopausal breast cancer. In Iacobelli & Di Marco (Eds) Role of medroxyprogesterone acetate in endocrine related tumors, pp. 65–71, Raven Press, New York, 1980

    Google Scholar 

  • Mauriac L, Durand M, Avil A, Dilhuydy JM. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumours larger than 3cm. Annals of Oncology 2: 347–354, 1991

    PubMed  CAS  Google Scholar 

  • Mick R, Begg CB, Antman KH, Korzun AH, Frei E III. Diverse prognosis in metastatic breast cancer: who should be offered alternative initial therapies? Breast Cancer Research and Treatment 13: 33–38, 1989

    Article  PubMed  CAS  Google Scholar 

  • Moore M. Interpretation of results of chemotherapy trials in metastatic breast cancer. Journal of Clinical Oncology 4: 258, 1986

    Google Scholar 

  • Morton AR, Cantrill JA, Pillai GV, McMahon A, Anderson DC, et al. Sclerosis of lytic bone metastases after disodium aminohydroxypropilidene bisphosphonate (APD) in patients with breast carcinoma. British Medical Journal 297: 772–773, 1988

    Article  PubMed  CAS  Google Scholar 

  • Mouridsen HT, Palshof T, Brahm M, Rahbek T. Evaluation of single drug versus multiple-drug chemotherapy in the treatment of advanced breast cancer. Cancer Treatment Reports 61: 47–50, 1977

    PubMed  CAS  Google Scholar 

  • Mouridsen HT, Palshof T, Rose C. Therapeutic effect of tamoxifen alone versus tamoxifen in combination with gestagen and oestrogen in advanced breast cancer. In Henningsen et al. (Eds) Endocrine treatment of breast cancer, pp. 169–177, Springer-Verlag, New York, 1980

    Chapter  Google Scholar 

  • Muss H, Case LD, Fusseil R, McCulloch J, O’Rouke M, et al. Tamoxifen (T) versus high dose oral medroxyprogesterone acetate (MPA) as first line endocrine therapy (RX) for metastatic breast cancer (MBC): a randomized trial for the Piedmont Oncology Association. Abstract 38. Proceedings of the American Society of Clinical Oncology 10: 41, 1991

    Google Scholar 

  • Muss HB, Richards F II, Jackson DV, Cooper MR, White DR, et al. Vincristine, doxorubicin, and cyclophosphamide versus low-dose intravenous cyclophosphamide, methotrexate and 5-fluorouracil in advanced breast cancer. A randomized trial of the Piedmont Oncology Association. Cancer 50: 2269–2274, 1982

    Article  PubMed  CAS  Google Scholar 

  • Muss HB, White DR, Richards F II, Cooper MR, Stuart JJ, et al. Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer: a randomized trial. Cancer 42: 2141–2148, 1978

    Article  PubMed  CAS  Google Scholar 

  • Nash CH III, Jones SE, Moon TE, Davis SL, Salmon SE. Prediction of outcome in metastatic breast cancer treated with adriamycin combination therapy. Cancer 46: 2380–2388, 1980

    Article  PubMed  Google Scholar 

  • OKunewick JP, Buffo MJ, Kociban DL. Comparative toxicity of mitoxantrone and doxorubicin on hematopoietic stem cells. Experimental Hematology 16: 23–30, 1985

    Google Scholar 

  • Pannuti F, Martoni A, Zamagni C, Melotti B. Progestins I: medroxyprogesterone acetate. In Powles & Smith (Eds) Medical Management of Breast Cancer, pp. 95–103, Martin Dunitz, London, 1991

    Google Scholar 

  • Patel JK, Nemoto T, Vezeridis M, Petrelli N, Suh O, et al. Does more intense palliative treatment improve overall survival in metastatic breast cancer patients. Cancer 57: 567–570, 1986

    Article  PubMed  CAS  Google Scholar 

  • Pedrazzini A, Cavalli F, Brunner KW, Goldhirsch A, Mermillod B. Complete remission following endocrine or combined cytotoxic and hormonal treatment in advanced breast cancer. A retrospective analysis. Oncology 44: 51–59, 1987

    Article  PubMed  CAS  Google Scholar 

  • Perloff M, Hart RD, Holland JF. Vinblastine, adriamycin, thiotepa and halotestin (VATH): therapy for advanced breast cancer refractory to prior chemotherapy. Cancer 42: 2534–2537, 1978

    Article  PubMed  CAS  Google Scholar 

  • Petru E, Schmähl D. On the role of additive hormone monotherapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer. Klinische Wochenschrift 65: 959–966, 1987

    Article  PubMed  CAS  Google Scholar 

  • Petru E, Schmähl D. No relevant influence on overall survival time in patients with metastatic breast cancer undergoing combination chemotherapy. Journal of Cancer Research and Clinical Oncology 114: 183–185, 1988

    Article  PubMed  CAS  Google Scholar 

  • Pocock SJ, Simon R. Sequential treatment assignments with balancing for prognostic factors in the controlled clinical trial. Biometrics 31: 103–115, 1975

    Article  PubMed  CAS  Google Scholar 

  • Powles TJ. Advanced breast cancer — new approaches to treatment: a review. European Journal of Cancer and Clinical Oncology 20: 95–98, 1988

    Article  Google Scholar 

  • Powles TJ. Progestins II: megestrol acetate. In Powles & Smith (Eds) Medical management of breast cancer, pp. 105–107, Martin Dunitz, London, 1991

    Google Scholar 

  • Powles TJ, Ashley SE, Ford HT, Gazet JC, Nash AG, et al. Treatment of disseminated breast cancer with tamoxifen aminoglutethimide, hydrocortisone and danazol used in combination or sequentially. Lancet 2: 369–373, 1984

    Google Scholar 

  • Raats JI, Falkson G, Falkson HC. A study of Fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer. Journal of Clinical Oncology 10: 111–116, 1992

    PubMed  CAS  Google Scholar 

  • Rivkin S, Green S, Metch B, Cruz A, McDivitt R, et al. Adjuvant combination chemotherapy (CMFVP) versus tamoxifen (TAM) vs CMFVP + TAM for postmenopausal women with ER+operable breast cancer and positive axillary lymph nodes: an intergroup study. Proceedings of the American Society of Clinical Oncology 9: 24, 1990

    Google Scholar 

  • Rose C, Kamby C, Mouridsen HT, Bastholt L, Brickner H, et al. Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide and hydrocortisone. Breast Cancer Research and Treatment 7: 545–550, 1986

    Google Scholar 

  • Rossof AH, Gelman R, Creech RH. Randomized evaluation of combination chemotherapy versus observation alone following response or stabilization after oophorectomy for metastatic breast cancer in premenopausal women. American Journal of Clinical Oncology — Cancer Clinical Trials 5: 253–259, 1982

    Article  CAS  Google Scholar 

  • Skeel RT, Andersen JW, Tormey DC, Benson AB III, Ashbury RF, et al. Combination chemotherapy of advanced breast cancer. Comparison of dibromodulcitol, doxorubicin, vincristine, and fluoxymesterone to thiotepa, doxorubicin, vinblastine and fluoroxymesterone: an Eastern Cooperative Oncology Group Study. Cancer 64: 1393–1399, 1989

    Article  PubMed  CAS  Google Scholar 

  • Smalley RV, Carpenter J, Bartolucci A, Vogel C, Krauss S. A comparison of cyclophosphamide, adriamycin, 5-flourouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. A South Eastern Cancer Study Group Project. Cancer 40: 625–632, 1977

    Article  PubMed  CAS  Google Scholar 

  • Smalley RV, Lefante J, Bartolucci A, Carpenter J, Vogel C, et al. A comparison of cyclophosphamide, adriamycin and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone (CMFVP) in patients with advanced breast cancer. Breast Cancer Research and Treatment 3: 209–220, 1983

    Article  PubMed  CAS  Google Scholar 

  • Smalley RV, Murphy S, Huguley CM Jr, Bartolucci A. Combination vs sequential 5-drug chemotherapy in metastatic carcinoma of the breast. Cancer Research 36: 3911–3916, 1976

    PubMed  CAS  Google Scholar 

  • Smith IE. Primary (neoadjuvant) medical therapy: introduction. In Powles & Smith (Eds) Medical management of breast cancer, pp. 259–265, Martin Dunitz, London, 1991

    Google Scholar 

  • Smith IE, Harris AL, Morgan M, Ford HT, Gazet JC, et al. Tamoxifen versus aminoglutethamide in advanced breast carcinoma: a randomized cross-over trial. British Medical Journal 283: 1432–1434, 1981

    Article  PubMed  CAS  Google Scholar 

  • Smith IE, Harris AL, Morgan M, Gazet JC, McKinna JA. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Cancer Research 42: 3430s–3433s, 1982

    PubMed  CAS  Google Scholar 

  • Taylor DG IV, Gelman RS, Falkson G, Cummings FJ. Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women (EST 7177). Annals of Internal Medicine 104: 455–461, 1986

    PubMed  Google Scholar 

  • Taylor SG, Knuiman MW, Sleeper LA, Olson JE, Tormey DC, et al. Six year results of the Eastern Cooperative Oncology Group Trial of observation versus CMFP versus CMFPT in postmenopausal patients with node-positive breast cancer. Journal of Clinical Oncology 7: 879–889, 1989

    PubMed  Google Scholar 

  • Tormey DC, Falkson G, Crowley J, Falkson HC, Voelkel J, et al. Dibromodulcitol and adriamycin ± tamoxifen in advanced breast cancer. American Journal of Clinical Oncology — Cancer Clinical Trials 5: 33–39, 1982a

    CAS  Google Scholar 

  • Tormey DC, Falkson G, Simon RM, Blom J, Bull JM, et al. A randomized comparison of two sequentially administered combination regimens to a single regimen in metastatic breast cancer. American Journal of Clinical Oncology — Cancer Clinical Trials 2: 247–256, 1979

    Google Scholar 

  • Tormey DC, Gelman R, Band PR, Sears M, Rosenthal SN, et al. Comparison of induction chemotherapies for metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. Cancer 50: 1235–1244, 1982b

    Article  PubMed  CAS  Google Scholar 

  • Tormey DC, Gelman R, Falkson G. Prospective evaluation of rotating chemotherapy in advanced breast cancer. An Eastern Cooperative Oncology Group Trial. American Journal of Clinical Oncology — Cancer Clinical Trials 6: 1–18, 1983

    CAS  Google Scholar 

  • Tormey DC, Simon R, Falkson G, Bull J, Band P, et al. Evaluation of adriamycin and dibromodulcitol in metastatic breast carcinoma. Cancer Research 37: 529–534, 1977

    PubMed  CAS  Google Scholar 

  • Tormey DC, Weinberg VE, Leone LA, Glidewell OJ, Perloff M, et al. A comparison of intermittent versus continuous and of adriamycin versus methotrexate 5-drug chemotherapy for advanced breast cancer. A Cancer and Leukemia Group B Study. American Journal of Clinical Oncology 7: 231–239, 1984

    Article  PubMed  CAS  Google Scholar 

  • Valagussa P, Tancini G, Bonadonna G. Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy. Cancer 58: 1411–1417, 1986

    Article  PubMed  CAS  Google Scholar 

  • Valavaara R, Pyrhoenen S. Low dose toremifene in the treatment of estrogen receptor positive advanced breast cancer in postmenopausal women. Current Therapy Research 46: 966–973, 1989

    Google Scholar 

  • van Holten-Verzantvoort AT, Bijvoet OLM, Cleton FJ, Hermans J, Kroon MH, et al. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet 2: 983–985, 1987

    Article  PubMed  Google Scholar 

  • Van Veelen H, Willemse PHB, Tjabbes T, Schweitzer MJH, Sleijfer DTh. Oral high-dose medroxyprogesterone acetate versus tamoxifen. Cancer 58: 7–13, 1986

    Article  PubMed  Google Scholar 

  • Varini M, Cavalli F, Brunner K, Martz G, Bartlomé EF, et al. High response to high-dose medroxyprogesterone acetate does not improve overall survival of postmenopausal patients with metastatic breast cancer. Proceedings of the American Society of Clinical Oncology 8: 46, 1989

    Google Scholar 

  • Viladiu P, Alonso MC, Avella A, Beltràn M, Borràs J, et al. Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients. A randomized trial. Cancer 56: 2745–2750, 1985

    Article  PubMed  CAS  Google Scholar 

  • Vincent MD, Powles TJ, Coombes RC, McElwain TJ. Late intensification with high dose melphalan plus autologous bone marrow support in breast cancer. Patients responding to conventional chemotherapy. Cancer Chemotherapy and Pharmacology 21: 255–260, 1988

    PubMed  CAS  Google Scholar 

  • Witte RS, Pruitt B, Tormey DC, Moss S, Rose DP, et al. A phase I/II investigation of trioxifene mesylate in advanced breast cancer: clinical and endocrinological effects. Cancer 57: 34–39, 1986

    Article  PubMed  CAS  Google Scholar 

  • Willemse PHB, van der Pleog E, Sleijfer DTH, Tjabbes T, van Veelen H. A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer. European Journal of Cancer 26: 337–343, 1990

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, University of Pretoria, P.O. Box 667, Pretoria, 0001, Republic of South Africa

    Carla I. Falkson,  Geoffrey Falkson & Hendre C. Falkson

Authors
  1. Carla I. Falkson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Geoffrey Falkson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hendre C. Falkson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Falkson, C.I., Falkson, G. & Falkson, H.C. Postmenopausal Breast Cancer. Drugs & Aging 3, 106–121 (1993). https://doi.org/10.2165/00002512-199303020-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199303020-00002

Keywords

Search

Navigation